Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Oct 17;28(3):672–683. doi: 10.1038/s41391-024-00906-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 2 — A Treatment selection algorithm for mCRPC in patients with progressive disease following treatment with an ARPI. B Treatment selection algorithm for mCRPC in patients without prior ARPI. ADT androgen deprivation therapy, ARPI androgen receptor pathway inhibitor, CRPC castration-resistant prostate cancer, CT computed tomography, HRR homologous recombination repair, Lu lutetium, mCRPC metastatic castration-resistant prostate cancer, MSI-H microsatellite instability-high, PARP poly (ADP-ribose) polymerase, PET positron emission tomography, PSMA prostate-specific membrane antigen, TMB tumor mutational burden. *If aggressive mCRPC disease features (e.g., liver metastases, short time to CRPC, multiple lytic bone lesions), prioritize taxane chemotherapy (consider adding carboplatin) if a candidate.